(6S)-1-{[4-(dimethylamino)-3-methylphenyl]methyl}-5-(2,2-diphenylacetyl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-6-carboxylic acid; trifluoroacetic acid

• ChemBase ID: 176242
• Molecular Formular: C33H33F3N4O5
• Molecular Mass: 622.6341296
• Monoisotopic Mass: 622.24030484
• SMILES: c1cccc(c1)C(c1ccccc1)C(=O)N1Cc2c(C[C@H]1C(=O)O)n(cn2)Cc1ccc(c(c1)C)N(C)C.C(=O)(O)C(F)(F)F
• Canonical SMILES: OC(=O)C(F)(F)F.OC(=O)[C@@H]1Cc2c(CN1C(=O)C(c1ccccc1)c1ccccc1)ncn2Cc1ccc(c(c1)C)N(C)C
• InChI: InChI=1S/C31H32N4O3.C2HF3O2/c1-21-16-22(14-15-26(21)33(2)3)18-34-20-32-25-19-35(28(31(37)38)17-27(25)34)30(36)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24;3-2(4,5)1(6)7/h4-16,20,28-29H,17-19H2,1-3H3,(H,37,38);(H,6,7)/t28-;/m0./s1
• InChIKey: ODNCUUDQKVCVBG-JCOPYZAKSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (6S)-1-{[4-(dimethylamino)-3-methylphenyl]methyl}-5-(2,2-diphenylacetyl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-6-carboxylic acid; trifluoroacetic acid
• IUPAC Traditional name: (6S)-1-{[4-(dimethylamino)-3-methylphenyl]methyl}-5-(2,2-diphenylacetyl)-4H,6H,7H-imidazo[4,5-c]pyridine-6-carboxylic acid; trifluoroacetic acid
• Synonyms: (6S)-1-[[4-(Dimethylamino)-3-methylphenyl]methyl]-5-(2,2-diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic Acid Bis(trifluoroacetate) Salt Hydrate; (S)-(+)-PD 123319 Bis(trifluoroacetate) Salt Hydrate; PD-123319 Bis(trifluoroacetate) Salt Hydrate

Database IDs

• PubChem SID: 164232152
• PubChem CID: 71751471

CALCULATED PROPERTIES

• Acid pKa: 3.7872865
• H Acceptors: 5
• H Donor: 1
• LogD (pH = 5.5): 3.0319395
• LogD (pH = 7.4): 1.8827649
• Log P: 2.9305005
• Molar Refractivity: 148.8024 cm^3
• Polarizability: 56.302113 Å^3
• Polar Surface Area: 78.67 Å^2
• Rotatable Bonds: 8
• Lipinski's Rule of Five: false

PROPERTIES

Physical Property

• Solubility: Chloroform; Methanol
• Apperance: Pale Beige Solid
• Melting Point: 111-114°C

Safety Information

• Storage Condition: Refrigerator

DETAILS

Toronto Research Chemicals - P217475

A selective and potent non-peptide angiotensin II type 2 (AT2) receptor antagonist. Potential treatment of cardiac hypertrophy as blockage of AT2 receptor prevents thyroxine-mediated cardiac hypertrophy by blocking Akt activation. Studies show that it has

REFERENCES

• Carmeiros-Ramos, M.S. et al.: Bas. Res, Cardiol., 105, 325 (2010)
• Kagawa, T. et al.: Nephrol., 13, 309 (2010)
• Cohen, E.P. et al.: Transl. Res., 150, 106 (2010)